Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial - Poll - MDSpire

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • By

  • Zhiqiang Zhong

  • Hongjuan Lu

  • Ting Li

  • Lingying Ye

  • Ling Zhou

  • Xiaobing Wang

  • Xin Wu

  • Huji Xu

  • June 23, 2026

  • 0 min

Share

Original Source(s)

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • by Zhiqiang Zhong, Hongjuan Lu, Ting Li, Lingying Ye, Ling Zhou, Xiaobing Wang, Xin Wu, Huji Xu

  • June 23, 2026

Related Content

Development and validation of a uric acid-inflammation-metabolism score for predicting osteoarthritis risk: evidence from NHANES 2007–2018 and an external Chinese cohort

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry